title: Prognostic factors in crescentic glomerulonephritis: a single-center experience.
abstract: BACKGROUND
  Crescentic glomerulonephritis (CGN) is a fatal disease, rapidly leading to end-stage renal disease. Diagnosis should be accurate and treatment should be started immediately. We investigated the factors associated with the renal prognosis in CGN patients.
  
  
  METHODS
  Forty-one patients with CGN who were followed up at the Nephrology Clinic of Ankara Numune Education and Research Hospital were divided into 2 arms of the dialysis-dependent group after treatment and the group that was followed up without dialysis. Demographic and clinical features along with biopsy findings during time of diagnosis were evaluated for both groups.
  
  
  RESULTS
  The mean age was 41.3 ± 17.2 years old and 26 were men. Twenty patients developed end-stage renal disease, requiring long-term dialysis. The dialysis-dependent group had higher serum creatinine levels (8.2 ± 3.6 mg/dL versus 2.6 ± 2.5 mg/dL) and percentages of glomeruli with crescent (83.1 ± 19.1% versus 56.4 ± 11.9%), were more likely to have oligoruia-anuria (90.5% versus 9.5%) and be dialysis-dependent at admission (86.4% versus 13.6%), and had longer elapsed time until the beginning of treatment (18.9 ± 10.4 days versus 10.6 ± 3.0 days) after treatment. At admission, their serum creatinine was greater than 4.2 mg/dL and the rate of crescentic glomeruli was greater than 63%.
  
  
  CONCLUSIONS
  In patients with CGN, renal prognosis is poor and the time of admission to the hospital, degree of renal insufficiency, presence of oligo-anuria, dialysis requirement, and the percentage of crescentic glomeruli on biopsy are closely related to progression to end-stage renal disease.
authors.forename: Ramazan
authors.initials: R
authors.lastname: Ozturk
authors.affiliation: Ankara Numune Education and Research Hospital, Department of Nephrology, Ankara, Turkey. drezgi_76@hotmail.com.
authors.forename: Ezgi Coskun
authors.initials: EC
authors.lastname: Yenigun
authors.forename: Fatih
authors.initials: F
authors.lastname: Dede
authors.forename: Eyup
authors.initials: E
authors.lastname: Koc
authors.forename: Didem
authors.initials: D
authors.lastname: Turgut
authors.forename: Serhan Vahit
authors.initials: SV
authors.lastname: Piskinpasa
authors.forename: Nihal
authors.initials: N
authors.lastname: Ozkayar
authors.forename: Ali Riza
authors.initials: AR
authors.lastname: Odabas
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000209:etiology*; D007678:Kidney Glomerulus / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011237:Predictive Value of Tests; D006435:Renal Dialysis; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014421:Turkey; D055815:Young Adult
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D003404:Creatinine